Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31062514 | 0.99 | PNMT (0.40) | PNMTPRCPHRH3KAT2BNSD2 | |
| SCHEMBL24914012 | 0.94 | PNMT (0.44) | PNMTPRCPHRH3KAT2BNSD2 | |
| Hydrochloric Acid SCHEMBL31062565 | 0.92 | PNMT (0.43) | PNMTPRCPHRH3NSD2CD44 | |
| SCHEMBL31062557 | 0.82 | PIM1 (0.40) | PNMTPRCPNSD2 | |
| SCHEMBL24913861 | 0.82 | PIM1 (0.40) | PNMTPRCPNSD2 | |
| SCHEMBL31062507 | 0.82 | PIM1 (0.40) | PNMTPRCPNSD2 | |
| SCHEMBL24913863 | 0.82 | PIM1 (0.40) | PNMTPRCPNSD2 | |
| SCHEMBL24913951 | 0.82 | PNMT (0.39) | PNMTPRCPHRH3 | |
| SCHEMBL24914018 | 0.81 | PNMT (0.38) | PNMTPRCPHRH3PIK3CDPIK3C2B | |
| Hydrochloric Acid SCHEMBL31062418 | 0.81 | PIM1 (0.38) | PNMTPRCPHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | PNMT 1748/4885PRCP 2632/4885HRH3 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.